AnaptysBio’s (ANAB) Outperform Rating Reiterated at Wedbush

AnaptysBio (NASDAQ:ANAB)‘s stock had its “outperform” rating reiterated by research analysts at Wedbush in a research report issued on Wednesday,RTT News reports. They currently have a $40.00 price objective on the biotechnology company’s stock, down from their previous price objective of $42.00. Wedbush’s price objective points to a potential upside of 157.90% from the company’s current price.

Several other research firms have also commented on ANAB. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. UBS Group lifted their target price on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. HC Wainwright lowered AnaptysBio from a “buy” rating to a “neutral” rating and decreased their price target for the company from $52.00 to $19.00 in a research note on Wednesday. Guggenheim raised their price objective on AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Truist Financial boosted their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.45.

AnaptysBio Stock Down 32.8 %

Shares of AnaptysBio stock traded down $7.58 on Wednesday, hitting $15.51. 4,098,777 shares of the company were exchanged, compared to its average volume of 377,908. The company has a 50-day moving average price of $26.72 and a 200 day moving average price of $29.68. The stock has a market capitalization of $471.97 million, a price-to-earnings ratio of -2.55 and a beta of -0.11. AnaptysBio has a 1-year low of $14.20 and a 1-year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. Research analysts forecast that AnaptysBio will post -6.02 EPS for the current year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the sale, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. This represents a 72.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the transaction, the insider now owns 15,398 shares of the company’s stock, valued at $595,440.66. The trade was a 8.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,440 shares of company stock valued at $892,936 in the last three months. 33.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AnaptysBio

Large investors have recently modified their holdings of the company. Barclays PLC increased its stake in AnaptysBio by 117.4% in the third quarter. Barclays PLC now owns 44,300 shares of the biotechnology company’s stock valued at $1,486,000 after purchasing an additional 23,926 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of AnaptysBio by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company’s stock valued at $15,594,000 after buying an additional 13,336 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in shares of AnaptysBio by 2.0% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after buying an additional 43,598 shares in the last quarter. XTX Topco Ltd grew its position in shares of AnaptysBio by 49.1% in the 3rd quarter. XTX Topco Ltd now owns 20,286 shares of the biotechnology company’s stock valued at $680,000 after buying an additional 6,683 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in AnaptysBio by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 65,939 shares of the biotechnology company’s stock worth $2,209,000 after acquiring an additional 3,048 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.